Moderna receives full FDA approval: is it time to buy the stock?

Moderna Inc (NASDAQ: MRNA) is now in the “oversold” territory after a 65% hit to its stock price over the past six months, says Sanctuary Wealth’s chief investment officer. Why Kilburg likes Moderna On CNBC’s “Power Lunch”, Jeff Kilburg said he was interested in owning Moderna on sale as the company had promising prospects for […]